attyloid’s sFIDA Technology Key in Revealing COVID-19’s Potential Neurodegenerative Impact
A new study has utilized attyloid’s cutting-edge Single Molecule Fluorescence Intensity Distribution Analysis (sFIDA) technology to explore how COVID-19 may induce tau protein aggregation, a factor in neurodegenerative diseases like Alzheimer’s. The research focuses on the role of SARS-CoV-2’s 3CL protease, finding that it can cleave tau protein, leading to its aggregation. Our pivotal findings prompt further investigation into COVID-19’s long-term effects on brain health.